Mucopolysaccharidosis

Mendelian MONDO:0019249 Pathograph 26 Metabolic Bone Disorders Lysosomal Storage Disorders

The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of enzymes required for degradation of glycosaminoglycans (GAGs). Undegraded GAGs accumulate in lysosomes and extracellular matrix, causing progressive multisystem disease. Skeletal manifestations (dysostosis multiplex) are a unifying feature across all MPS types, including vertebral abnormalities, joint contractures, short stature, and characteristic radiographic changes. Enzyme replacement therapy and hematopoietic stem cell transplantation are available for several subtypes.

Ask OpenScientist

Ask a research question about Mucopolysaccharidosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
1
Inheritance
5
Pathophysiology
0
Histopathology
8
Phenotypes
26
Pathograph
11
Genes
3
Treatments
0
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
4
References
2
Deep Research
👪

Inheritance

1
Autosomal Recessive
All MPS types are autosomal recessive except MPS II (Hunter syndrome), which is X-linked recessive.
⚙

Pathophysiology

5
Lysosomal GAG Accumulation
Deficiency of specific lysosomal enzymes leads to accumulation of undegraded glycosaminoglycans (dermatan sulfate, heparan sulfate, keratan sulfate, chondroitin sulfate, or hyaluronan depending on the subtype). GAGs accumulate in lysosomes of connective tissue cells, causing cellular dysfunction and tissue/organ damage. In bone and cartilage, GAG storage disrupts endochondral ossification, growth plate organization, and articular cartilage integrity.
Chondrocyte link
IDUA link IDS link SGSH link NAGLU link HGSNAT link GNS link GALNS link GLB1 link ARSB link GUSB link HYAL1 link
Glycosaminoglycan Catabolism link ↓ DECREASED Lysosomal Transport link
Lysosome link
Downstream
Secondary Inflammatory Response Progressive lysosomal GAG storage elicits TLR4-initiated innate immune activation.
Skeletal and connective-tissue storage pathology GAG storage in cartilage and connective tissues disrupts skeletal development and joint integrity.
Visceral and cardiorespiratory storage burden Systemic GAG storage affects liver, spleen, airways, and cardiac valves.
CNS storage and neuroinflammation Neuronopathic MPS subtypes with heparan-sulfate storage develop CNS dysfunction and inflammatory amplification.
Show evidence (4 references)
PMID:35216110 SUPPORT Other
"Mucopolysaccharidoses are rare paediatric lysosomal storage disorders, characterised by accumulation of glycosaminoglycans within lysosomes"
Confirms MPS as lysosomal storage disorders with GAG accumulation.
PMID:35216110 SUPPORT Other
"caused by deficiencies in lysosomal enzymes involved in degradation of these molecules"
Confirms enzyme deficiency as the underlying cause of GAG accumulation.
PMID:32780955 SUPPORT Human Clinical
"Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disorder, caused by deficiency of α-L-iduronidase, and consequent accumulation of dermatan and heparan sulfates"
Specific example of enzyme deficiency (alpha-L-iduronidase) causing GAG accumulation in MPS I.
+ 1 more reference
Secondary Inflammatory Response
Accumulated GAGs and their fragments activate toll-like receptors (TLR4) and inflammasome pathways, driving chronic inflammation that contributes to joint destruction, cardiac valve disease, and neurodegeneration. GAG-mediated inflammation amplifies tissue damage beyond direct storage effects.
Inflammatory Response link ↑ INCREASED
Downstream
Skeletal and connective-tissue storage pathology TNF-alpha-mediated inflammation contributes to MPS bone and joint disease.
CNS storage and neuroinflammation IL-1 and NLRP3 inflammasome activity amplify CNS inflammatory injury in neuronopathic MPS.
Show evidence (3 references)
PMID:35216110 SUPPORT Other
"We propose a model whereby progressive accumulation of glycosaminoglycans elicits an innate immune response, initiated by the Toll-like receptor 4 pathway"
Proposes TLR4-mediated innate immune activation by accumulated GAGs as key secondary mechanism.
PMID:35216110 SUPPORT Other
"While TNF-α is mostly associated with bone and joint disease in mucopolysaccharidoses, increasing evidence implicates IL-1 as a main effector of innate immunity in the central nervous system"
Distinguishes inflammatory mediators: TNF-alpha drives skeletal disease, IL-1 drives CNS inflammation.
PMID:35216110 SUPPORT Other
"progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure, and in others, to cognitive decline"
GAG accumulation leads to progressive multisystem damage including musculoskeletal and cognitive decline.
Skeletal and connective-tissue storage pathology
GAG storage in cartilage, bone, cornea, and periarticular connective tissue disrupts growth-plate organization, endochondral ossification, and tissue mechanics, producing dysostosis multiplex, short stature, joint stiffness or laxity, coarse facial features, and corneal opacity.
Chondrocyte link
Endochondral ossification link ↓ DECREASED Glycosaminoglycan Catabolism link ↓ DECREASED
Downstream
Dysostosis Multiplex Skeletal storage pathology produces the characteristic dysostosis multiplex radiographic pattern.
Short Stature Disrupted endochondral ossification and skeletal dysplasia cause progressive growth failure.
Joint Contractures Periarticular storage and inflammatory joint disease produce progressive stiffness and contractures.
Coarse Facial Features Progressive connective-tissue and soft-tissue storage contributes to coarse facial features.
Corneal Clouding Connective-tissue GAG deposition in the cornea produces corneal opacity.
Show evidence (2 references)
PMID:25346323 SUPPORT Human Clinical
"The skeletal manifestations are generally more extensive and severe than in other types of MPS disorders."
Morquio A guidelines support prominent skeletal pathology from MPS storage disease.
PMID:32780955 SUPPORT Human Clinical
"A prominent clinical manifestation of MPS-IH is dysostosis multiplex, a constellation of skeletal abnormalities."
MPS I-H review supports dysostosis multiplex as a skeletal manifestation of MPS storage pathology.
Visceral and cardiorespiratory storage burden
Systemic lysosomal GAG storage enlarges liver and spleen and affects cartilaginous airways, bronchi, cardiac valves, and other somatic organs, producing multisystem morbidity that is partly responsive to enzyme replacement.
Glycosaminoglycan Catabolism link ↓ DECREASED
Lysosome link
Downstream
Hepatosplenomegaly Reticuloendothelial GAG storage enlarges liver and spleen.
Cardiac Valve Disease GAG storage in cardiac valves contributes to valve thickening and dysfunction.
Show evidence (2 references)
PMID:30442189 SUPPORT Human Clinical
"liver and spleen volume, cartilaginous organs such as the trachea and bronchi, bones and eyes are poorly impacted by ERT"
ERT review identifies hepatosplenic, airway, skeletal, and ocular somatic compartments affected by MPS storage and treatment penetration.
PMID:38085235 SUPPORT Model Organism
"life-threatening respiratory and cardiac complications."
MPS II model paper summarizes respiratory and cardiac complications of systemic GAG storage disease.
CNS storage and neuroinflammation
Neuronopathic MPS subtypes, especially those with heparan sulfate storage, develop CNS dysfunction that is compounded by IL-1/NLRP3-driven neuroinflammation; current intravenous enzyme replacement has limited CNS impact because it does not cross the blood-brain barrier.
Inflammatory Response link ↑ INCREASED Glycosaminoglycan Catabolism link ↓ DECREASED
Downstream
Intellectual Disability CNS storage and neuroinflammatory injury drive cognitive decline in neuronopathic MPS subtypes.
Show evidence (2 references)
PMID:35216110 SUPPORT Other
"increasing evidence implicates IL-1 as a main effector of innate immunity in the central nervous system"
Innate-immunity review supports CNS inflammatory amplification in MPS.
PMID:30442189 SUPPORT Human Clinical
"ERT in the present formulations also does not cross the blood-brain barrier, with the consequence that the central nervous system is not cured by ERT"
ERT review supports persistent CNS storage disease because intravenous ERT does not cross the blood-brain barrier.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Mucopolysaccharidosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Cardiovascular 2
Hepatosplenomegaly Hepatosplenomegaly (HP:0001433)
Show evidence (1 reference)
PMID:30442189 SUPPORT Human Clinical
"ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume"
Hepatosplenomegaly is a recognized MPS feature that responds to ERT, confirming organ enlargement from GAG storage.
Cardiac Valve Disease Abnormal heart valve morphology (HP:0001654)
Show evidence (1 reference)
PMID:33558080 SUPPORT Human Clinical
"heart valve defects due to keratan sulphate accumulation"
Morquio B patient series links GAG storage to heart valve defects, supporting the cardiac-valve node in the broader MPS spectrum.
Eye 1
Corneal Clouding Corneal opacity (HP:0007957)
Show evidence (1 reference)
PMID:28595941 SUPPORT Human Clinical
"Symptoms include coarse facial features, umbilical hernia, pectus carinatum, joint contractures, corneal clouding, and hepatosplenomegaly."
Epidemiology review lists corneal clouding among MPS VI symptoms, supporting corneal opacity within the MPS spectrum.
Head and Neck 1
Coarse Facial Features Coarse facial features (HP:0000280)
Show evidence (1 reference)
PMID:28595941 SUPPORT Human Clinical
"Clinical features include coarsening of facies"
Epidemiology review lists facial coarsening among clinical features of MPS IV, supporting soft-tissue facial involvement within the MPS spectrum.
Musculoskeletal 2
Dysostosis Multiplex Dysostosis multiplex (HP:0000943)
Show evidence (1 reference)
PMID:32780955 SUPPORT Human Clinical
"A prominent clinical manifestation of MPS-IH is dysostosis multiplex, a constellation of skeletal abnormalities"
Confirms dysostosis multiplex as a prominent skeletal manifestation of MPS.
Joint Contractures Joint stiffness (HP:0001387)
Show evidence (1 reference)
PMID:35216110 SUPPORT
"progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure"
Musculoskeletal abnormalities from GAG storage include progressive joint stiffness and contractures.
Nervous System 1
Intellectual Disability Intellectual disability (HP:0001249)
Show evidence (3 references)
PMID:30442189 SUPPORT
"ERT in the present formulations also does not cross the blood-brain barrier, with the consequence that the central nervous system is not cured by ERT"
CNS involvement causing intellectual disability is a major challenge as ERT cannot cross the blood-brain barrier.
PMID:35216110 SUPPORT Other
"in others, to cognitive decline, which is still a challenge for current therapies"
Cognitive decline is a characteristic feature that remains a therapeutic challenge in MPS.
PMID:25624320 SUPPORT
"Preservation of cognitive function at HCT and a younger age at transplantation were major predictors for superior cognitive development posttransplant"
Cognitive decline is a major concern in MPS I-H; early HCT can preserve cognitive function.
Growth 1
Short Stature Short stature (HP:0004322)
Show evidence (1 reference)
PMID:28595941 SUPPORT Human Clinical
"Abnormalities may include developmental delay, mental retardation, coarsening of facial features including thickening of lips, tongue, and nostrils, dysostosis multiplex, progressive growth delay resulting in short stature, and joint stiffness associated with restriction of movements."
Epidemiology review lists progressive growth delay resulting in short stature among MPS II clinical abnormalities, supporting short stature within the MPS spectrum.
🧬

Genetic Associations

11
MPS I (IDUA Mutations) (Causative)
Show evidence (3 references)
PMID:33578874 SUPPORT Human Clinical
"MPS I results from a mutation in the IDUA gene located on chromosome 4p16.3."
Review identifies IDUA mutation as causal for MPS I.
PMID:32780955 SUPPORT Human Clinical
"caused by deficiency of α-L-iduronidase, and consequent accumulation of dermatan and heparan sulfates"
Confirms alpha-L-iduronidase deficiency as the cause of MPS I with dermatan and heparan sulfate accumulation.
PMID:32780955 SUPPORT Human Clinical
"Severity of the disease ranges from mild (Scheie) to moderate (Hurler-Scheie) to severe (Hurler or MPS-IH)"
Confirms the clinical severity spectrum of MPS I from Scheie to Hurler.
MPS II (IDS Mutations) (Causative)
Show evidence (2 references)
PMID:30442189 SUPPORT Human Clinical
"This is particularly important for severe forms of MPS I and MPS II characterized by cognitive decline"
Confirms MPS II has severe forms with cognitive decline.
PMID:33578874 SUPPORT Human Clinical
"A mutation in the IDS gene, which locates on chromosome Xq28, leads to MPS II."
Review supports IDS as the causal X-linked MPS II gene.
MPS IIIA (SGSH Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"MPS IIIA arises from a mutation in the SGSH gene located on chromosome 17q25.3."
Review identifies SGSH mutation as causal for MPS IIIA.
MPS IIIB (NAGLU Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"A mutation in the NAGLU gene, located on chromosome 17q21, results in MPS IIIB disorder."
Review identifies NAGLU mutation as causal for MPS IIIB.
MPS IIIC (HGSNAT Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"Mutations in the HGSNAT gene, located on chromosome 8p11.1, cause MPS IIIC."
Review identifies HGSNAT mutation as causal for MPS IIIC.
MPS IIID (GNS Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"MPS IIID is caused by a mutation in the GNS gene locating on chromosome 12q14."
Review identifies GNS mutation as causal for MPS IIID.
MPS IVA (GALNS Mutations) (Causative)
Show evidence (1 reference)
PMID:25346323 SUPPORT Human Clinical
"It is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS) due to a mutation in the GALNS gene"
Morquio A guidelines identify GALNS mutations and enzyme deficiency as causal for MPS IVA.
MPS IVB (GLB1 Mutations) (Causative)
Show evidence (1 reference)
PMID:21497194 SUPPORT Human Clinical
"GM1 gangliosidosis and Morquio B are autosomal recessive storage disorders caused by the deficiency of β-galactosidase (GLB1)"
Review supports GLB1 beta-galactosidase deficiency as causal for Morquio B / MPS IVB.
MPS VI (ARSB Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"MPS VI is caused by a mutation in the ARSB (or 4S) gene located on chromosome 5q11–q13."
Review identifies ARSB mutation as causal for MPS VI.
MPS VII (GUSB Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"MPS VII is rooted in a mutation in the GUSB gene located on chromosome 7q21.11."
Review identifies GUSB mutation as causal for MPS VII.
MPS IX (HYAL1 Mutations) (Causative)
Show evidence (1 reference)
PMID:33578874 SUPPORT Human Clinical
"MPS IX arises from a mutation in the HYAL1 gene located on chromosome 3p21.3–p21.2."
Review identifies HYAL1 mutation as causal for MPS IX.
💊

Treatments

3
Enzyme Replacement Therapy
Action: pharmacotherapy MAXO:0000058
Intravenous recombinant enzyme infusions for MPS I (laronidase), MPS II (idursulfase), MPS IVA (elosulfase alfa), MPS VI (galsulfase), and MPS VII (vestronidase alfa). Improves somatic features but does not cross the blood-brain barrier effectively.
Mechanism Target:
RESTORES Lysosomal GAG Accumulation — Recombinant lysosomal enzymes reduce urinary GAGs and hepatosplenic storage burden in treatable MPS subtypes.
Show evidence (1 reference)
PMID:30442189 SUPPORT Human Clinical
"While ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume"
Review supports ERT-mediated reduction of the storage biomarker and hepatosplenic burden.
Show evidence (4 references)
PMID:30442189 SUPPORT
"Enzyme replacement therapy (ERT) is available for mucopolysaccharidosis (MPS) I, MPS II, MPS VI, and MPS IVA"
Confirms ERT availability for MPS I, II, VI, and IVA.
PMID:30442189 SUPPORT
"ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume, cartilaginous organs such as the trachea and bronchi, bones and eyes are poorly impacted by ERT probably due to limited penetration in the specific tissue"
ERT is effective for some features but has limited impact on cartilage, bones, and eyes.
PMID:30442189 SUPPORT
"ERT in the present formulations also does not cross the blood-brain barrier, with the consequence that the central nervous system is not cured by ERT"
Major limitation of ERT is inability to cross the blood-brain barrier for CNS disease.
+ 1 more reference
Hematopoietic Stem Cell Transplantation
Action: hematopoietic stem cell transplantation MAXO:0000747
HSCT provides a permanent source of enzyme-producing donor cells. Most effective when performed before age 2 in MPS I-H (Hurler). Can stabilize neurocognitive outcomes by providing CNS enzyme via donor-derived microglia.
Mechanism Target:
RESTORES Lysosomal GAG Accumulation — Donor-derived hematopoietic cells can restore lysosomal enzyme activity, especially in severe MPS I.
Show evidence (1 reference)
PMID:25624320 SUPPORT Human Clinical
"A normal α-l-iduronidase enzyme level obtained post-HCT was another highly significant predictor for superior long-term outcome in most organ systems"
HCT outcome study supports restored alpha-L-iduronidase activity as a determinant of improved organ outcomes.
MODULATES CNS storage and neuroinflammation — Early HCT can preserve neurocognitive outcomes when performed before substantial cognitive decline.
Show evidence (1 reference)
PMID:25624320 SUPPORT Human Clinical
"Preservation of cognitive function at HCT and a younger age at transplantation were major predictors for superior cognitive development posttransplant"
HCT cohort links early transplantation and pre-existing cognitive status to superior cognitive outcomes.
Show evidence (5 references)
PMID:30442189 SUPPORT
"For severe MPS I patients (Hurler), early haematopoietic stem cell transplantation is the gold standard"
Confirms HSCT as gold standard for severe MPS I.
PMID:25624320 SUPPORT
"Two hundred seventeen patients with MPS-IH successfully engrafted with a median follow-up age of 9.2 years were included in this retrospective analysis"
Large multicenter study of 217 HCT patients demonstrates long-term outcomes.
PMID:25624320 SUPPORT
"Considerable residual disease burden was observed in the majority of the transplanted patients with MPS-IH, with high variability between patients"
Despite HCT, substantial residual disease burden persists, highlighting limitations of current treatment.
+ 2 more references
Supportive Orthopedic Care
Action: surgical procedure MAXO:0000004
Spinal surgery for cervical instability (especially MPS IV), joint replacement, carpal tunnel release, and management of kyphosis and scoliosis.
Show evidence (3 references)
PMID:25346323 SUPPORT Human Clinical
"hip subluxation can be managed using pelvic and femoral osteotomy, shelf acetabuloplasty, or total hip arthroplasty"
Guidelines support orthopedic surgical management for MPS skeletal complications.
PMID:25346323 SUPPORT Human Clinical
"Interventions for spinal cord compression in patients with Morquio A syndrome include spinal decompression, fusion or a combination of both"
Guidelines support spinal decompression and fusion for cord-compression complications.
PMID:32780955 SUPPORT
"thoracolumbar kyphosis is an early manifestation in humans"
Early skeletal manifestations like thoracolumbar kyphosis require orthopedic monitoring and intervention.
{ }

Source YAML

click to show 
name: Mucopolysaccharidosis
creation_date: '2026-02-13T00:31:42Z'
updated_date: '2026-05-09T14:04:00Z'
category: Mendelian
description: >
  The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused
  by deficiency of enzymes required for degradation of glycosaminoglycans (GAGs).
  Undegraded GAGs accumulate in lysosomes and extracellular matrix, causing
  progressive multisystem disease. Skeletal manifestations (dysostosis multiplex)
  are a unifying feature across all MPS types, including vertebral abnormalities,
  joint contractures, short stature, and characteristic radiographic changes.
  Enzyme replacement therapy and hematopoietic stem cell transplantation are
  available for several subtypes.
disease_term:
  preferred_term: Mucopolysaccharidosis
  term:
    id: MONDO:0019249
    label: mucopolysaccharidosis
parents:
- Metabolic Bone Disorders
- Lysosomal Storage Disorders
inheritance:
- name: Autosomal Recessive
  description: >
    All MPS types are autosomal recessive except MPS II (Hunter syndrome),
    which is X-linked recessive.
prevalence:
- population: Japan live births
  percentage: 1.53 per 100,000 live births
  notes: >-
    Population-based ascertainment in Japan found combined MPS birth
    prevalence just above 1.5 per 100,000 live births, with MPS II accounting
    for more than half of cases.
  evidence:
  - reference: PMID:28595941
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The combined birth prevalence was 1.53 per 100,000 live births."
    explanation: This epidemiology study provides a direct birth-prevalence estimate for MPS in Japan.
  - reference: PMID:33578874
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background."
    explanation: Updated international review supports interpreting national MPS prevalence estimates in a geographically stratified way.
- population: Switzerland live births
  percentage: 1.56 per 100,000 live births
  notes: >-
    Swiss registry-based ascertainment yielded a very similar combined birth
    prevalence to Japan, again with marked subtype-specific variation.
  evidence:
  - reference: PMID:28595941
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The combined birth prevalence was 1.56 per 100,000 live births."
    explanation: The same study provides a direct birth-prevalence estimate for MPS in Switzerland.
  - reference: PMID:33578874
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In total, data from 33 countries and 23 regions were compiled and analyzed."
    explanation: Updated international review shows that these national estimates sit within a broad global epidemiologic dataset.
pathophysiology:
- name: Lysosomal GAG Accumulation
  description: >
    Deficiency of specific lysosomal enzymes leads to accumulation of
    undegraded glycosaminoglycans (dermatan sulfate, heparan sulfate,
    keratan sulfate, chondroitin sulfate, or hyaluronan depending on
    the subtype). GAGs accumulate in lysosomes of connective tissue
    cells, causing cellular dysfunction and tissue/organ damage. In
    bone and cartilage, GAG storage disrupts endochondral ossification,
    growth plate organization, and articular cartilage integrity.
  genes:
  - preferred_term: IDUA
    term:
      id: hgnc:5391
      label: IDUA
  - preferred_term: IDS
    term:
      id: hgnc:5389
      label: IDS
  - preferred_term: SGSH
    term:
      id: hgnc:10818
      label: SGSH
  - preferred_term: NAGLU
    term:
      id: hgnc:7632
      label: NAGLU
  - preferred_term: HGSNAT
    term:
      id: hgnc:26527
      label: HGSNAT
  - preferred_term: GNS
    term:
      id: hgnc:4422
      label: GNS
  - preferred_term: GALNS
    term:
      id: hgnc:4122
      label: GALNS
  - preferred_term: GLB1
    term:
      id: hgnc:4298
      label: GLB1
  - preferred_term: ARSB
    term:
      id: hgnc:714
      label: ARSB
  - preferred_term: GUSB
    term:
      id: hgnc:4696
      label: GUSB
  - preferred_term: HYAL1
    term:
      id: hgnc:5320
      label: HYAL1
  biological_processes:
  - preferred_term: Glycosaminoglycan Catabolism
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  - preferred_term: Lysosomal Transport
    term:
      id: GO:0007041
      label: lysosomal transport
  chemical_entities:
  - preferred_term: glycosaminoglycan
    modifier: INCREASED
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
  cellular_components:
  - preferred_term: Lysosome
    term:
      id: GO:0005764
      label: lysosome
  cell_types:
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  evidence:
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mucopolysaccharidoses are rare paediatric lysosomal storage disorders, characterised by accumulation of glycosaminoglycans within lysosomes"
    explanation: "Confirms MPS as lysosomal storage disorders with GAG accumulation."
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "caused by deficiencies in lysosomal enzymes involved in degradation of these molecules"
    explanation: "Confirms enzyme deficiency as the underlying cause of GAG accumulation."
  - reference: PMID:32780955
    reference_title: "Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disorder, caused by deficiency of α-L-iduronidase, and consequent accumulation of dermatan and heparan sulfates"
    explanation: "Specific example of enzyme deficiency (alpha-L-iduronidase) causing GAG accumulation in MPS I."
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mucopolysaccharidoses (MPS) are a group of inherited metabolic disorders caused by the deficiency of lysosomal enzymes that degrade glycosaminoglycans (GAGs)."
    explanation: "Broad MPS review supports the class-level mechanism of subtype-specific lysosomal enzyme deficiency impairing GAG degradation."
  downstream:
  - target: Secondary Inflammatory Response
    causal_link_type: DIRECT
    description: Progressive lysosomal GAG storage elicits TLR4-initiated innate immune activation.
    evidence:
    - reference: PMID:35216110
      reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "progressive accumulation of glycosaminoglycans elicits an innate immune response, initiated by the Toll-like receptor 4 pathway"
      explanation: Review explicitly links accumulated GAGs to innate immune activation.
  - target: Skeletal and connective-tissue storage pathology
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: GAG storage in cartilage and connective tissues disrupts skeletal development and joint integrity.
    evidence:
    - reference: PMID:25346323
      reference_title: International guidelines for the management and treatment of Morquio A syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "due to the accumulation of storage material in tissues and organs, leading to cellular dysfunction, they progressively develop profound skeletal and joint abnormalities"
      explanation: Morquio A guidelines connect storage material to skeletal and joint pathology.
  - target: Visceral and cardiorespiratory storage burden
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Systemic GAG storage affects liver, spleen, airways, and cardiac valves.
    evidence:
    - reference: PMID:30442189
      reference_title: "Enzyme replacement therapy: efficacy and limitations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume"
      explanation: Somatic response to ERT supports GAG storage as an upstream driver of hepatosplenic enlargement.
  - target: CNS storage and neuroinflammation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Neuronopathic MPS subtypes with heparan-sulfate storage develop CNS dysfunction and inflammatory amplification.
    evidence:
    - reference: PMID:35216110
      reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure, and in others, to cognitive decline"
      explanation: Review links progressive storage burden to cognitive decline in neuronopathic MPS.
- name: Secondary Inflammatory Response
  description: >
    Accumulated GAGs and their fragments activate toll-like receptors
    (TLR4) and inflammasome pathways, driving chronic inflammation
    that contributes to joint destruction, cardiac valve disease,
    and neurodegeneration. GAG-mediated inflammation amplifies
    tissue damage beyond direct storage effects.
  biological_processes:
  - preferred_term: Inflammatory Response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We propose a model whereby progressive accumulation of glycosaminoglycans elicits an innate immune response, initiated by the Toll-like receptor 4 pathway"
    explanation: "Proposes TLR4-mediated innate immune activation by accumulated GAGs as key secondary mechanism."
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "While TNF-α is mostly associated with bone and joint disease in mucopolysaccharidoses, increasing evidence implicates IL-1 as a main effector of innate immunity in the central nervous system"
    explanation: "Distinguishes inflammatory mediators: TNF-alpha drives skeletal disease, IL-1 drives CNS inflammation."
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure, and in others, to cognitive decline"
    explanation: "GAG accumulation leads to progressive multisystem damage including musculoskeletal and cognitive decline."
  downstream:
  - target: Skeletal and connective-tissue storage pathology
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: TNF-alpha-mediated inflammation contributes to MPS bone and joint disease.
    evidence:
    - reference: PMID:35216110
      reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "TNF-α is mostly associated with bone and joint disease in mucopolysaccharidoses"
      explanation: Review identifies TNF-alpha inflammatory signaling as a contributor to MPS bone and joint pathology.
  - target: CNS storage and neuroinflammation
    causal_link_type: DIRECT
    description: IL-1 and NLRP3 inflammasome activity amplify CNS inflammatory injury in neuronopathic MPS.
    evidence:
    - reference: PMID:35216110
      reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "IL-1 as a main effector of innate immunity in the central nervous system"
      explanation: Review links IL-1 innate immune signaling to CNS involvement in MPS.
- name: Skeletal and connective-tissue storage pathology
  description: >
    GAG storage in cartilage, bone, cornea, and periarticular connective tissue
    disrupts growth-plate organization, endochondral ossification, and tissue
    mechanics, producing dysostosis multiplex, short stature, joint stiffness or
    laxity, coarse facial features, and corneal opacity.
  biological_processes:
  - preferred_term: Endochondral ossification
    modifier: DECREASED
    term:
      id: GO:0001958
      label: endochondral ossification
  - preferred_term: Glycosaminoglycan Catabolism
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  chemical_entities:
  - preferred_term: glycosaminoglycan
    modifier: INCREASED
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
  cell_types:
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The skeletal manifestations are generally more extensive and severe than in other types of MPS disorders."
    explanation: Morquio A guidelines support prominent skeletal pathology from MPS storage disease.
  - reference: PMID:32780955
    reference_title: "Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A prominent clinical manifestation of MPS-IH is dysostosis multiplex, a constellation of skeletal abnormalities."
    explanation: MPS I-H review supports dysostosis multiplex as a skeletal manifestation of MPS storage pathology.
  downstream:
  - target: Dysostosis Multiplex
    causal_link_type: DIRECT
    description: Skeletal storage pathology produces the characteristic dysostosis multiplex radiographic pattern.
  - target: Short Stature
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Disrupted endochondral ossification and skeletal dysplasia cause progressive growth failure.
  - target: Joint Contractures
    causal_link_type: DIRECT
    description: Periarticular storage and inflammatory joint disease produce progressive stiffness and contractures.
  - target: Coarse Facial Features
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Progressive connective-tissue and soft-tissue storage contributes to coarse facial features.
  - target: Corneal Clouding
    causal_link_type: DIRECT
    description: Connective-tissue GAG deposition in the cornea produces corneal opacity.
- name: Visceral and cardiorespiratory storage burden
  description: >
    Systemic lysosomal GAG storage enlarges liver and spleen and affects
    cartilaginous airways, bronchi, cardiac valves, and other somatic organs,
    producing multisystem morbidity that is partly responsive to enzyme
    replacement.
  biological_processes:
  - preferred_term: Glycosaminoglycan Catabolism
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  chemical_entities:
  - preferred_term: glycosaminoglycan
    modifier: INCREASED
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
  cellular_components:
  - preferred_term: Lysosome
    term:
      id: GO:0005764
      label: lysosome
  evidence:
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "liver and spleen volume, cartilaginous organs such as the trachea and bronchi, bones and eyes are poorly impacted by ERT"
    explanation: ERT review identifies hepatosplenic, airway, skeletal, and ocular somatic compartments affected by MPS storage and treatment penetration.
  - reference: PMID:38085235
    reference_title: Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "life-threatening respiratory and cardiac complications."
    explanation: MPS II model paper summarizes respiratory and cardiac complications of systemic GAG storage disease.
  downstream:
  - target: Hepatosplenomegaly
    causal_link_type: DIRECT
    description: Reticuloendothelial GAG storage enlarges liver and spleen.
  - target: Cardiac Valve Disease
    causal_link_type: DIRECT
    description: GAG storage in cardiac valves contributes to valve thickening and dysfunction.
- name: CNS storage and neuroinflammation
  description: >
    Neuronopathic MPS subtypes, especially those with heparan sulfate storage,
    develop CNS dysfunction that is compounded by IL-1/NLRP3-driven
    neuroinflammation; current intravenous enzyme replacement has limited CNS
    impact because it does not cross the blood-brain barrier.
  biological_processes:
  - preferred_term: Inflammatory Response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: Glycosaminoglycan Catabolism
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  chemical_entities:
  - preferred_term: glycosaminoglycan
    modifier: INCREASED
    term:
      id: CHEBI:18085
      label: glycosaminoglycan
  evidence:
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "increasing evidence implicates IL-1 as a main effector of innate immunity in the central nervous system"
    explanation: Innate-immunity review supports CNS inflammatory amplification in MPS.
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ERT in the present formulations also does not cross the blood-brain barrier, with the consequence that the central nervous system is not cured by ERT"
    explanation: ERT review supports persistent CNS storage disease because intravenous ERT does not cross the blood-brain barrier.
  downstream:
  - target: Intellectual Disability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: CNS storage and neuroinflammatory injury drive cognitive decline in neuronopathic MPS subtypes.
phenotypes:
- name: Dysostosis Multiplex
  description: >
    Characteristic skeletal radiographic pattern common to all MPS types,
    including J-shaped sella turcica, oar-shaped ribs, bullet-shaped
    vertebral bodies with anterior beaking, proximal metacarpal pointing,
    and flared iliac wings. Severity varies by subtype.
  phenotype_term:
    preferred_term: Dysostosis multiplex
    term:
      id: HP:0000943
      label: Dysostosis multiplex
  evidence:
  - reference: PMID:32780955
    reference_title: "Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A prominent clinical manifestation of MPS-IH is dysostosis multiplex, a constellation of skeletal abnormalities"
    explanation: "Confirms dysostosis multiplex as a prominent skeletal manifestation of MPS."
- name: Short Stature
  description: >
    Progressive growth failure due to disrupted endochondral ossification
    and growth plate dysfunction. Most severe in MPS I-H (Hurler),
    MPS IV (Morquio), and MPS VI (Maroteaux-Lamy).
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:28595941
    reference_title: Epidemiology of mucopolysaccharidoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormalities may include developmental delay, mental retardation, coarsening of facial features including thickening of lips, tongue, and nostrils, dysostosis multiplex, progressive growth delay resulting in short stature, and joint stiffness associated with restriction of movements."
    explanation: Epidemiology review lists progressive growth delay resulting in short stature among MPS II clinical abnormalities, supporting short stature within the MPS spectrum.
- name: Joint Contractures
  description: >
    Progressive joint stiffness and contractures from GAG storage in
    periarticular tissues. Present in most MPS types except MPS IV
    (Morquio), which features joint laxity instead.
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
  evidence:
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    snippet: "progressive build-up of sugars may lead to musculoskeletal abnormalities and multi-organ failure"
    explanation: "Musculoskeletal abnormalities from GAG storage include progressive joint stiffness and contractures."
- name: Coarse Facial Features
  description: >
    Progressive coarsening of facial features from GAG infiltration
    of soft tissues, including broad nasal bridge, thick lips,
    macroglossia, and frontal bossing.
  phenotype_term:
    preferred_term: Coarse facial features
    term:
      id: HP:0000280
      label: Coarse facial features
  evidence:
  - reference: PMID:28595941
    reference_title: Epidemiology of mucopolysaccharidoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical features include coarsening of facies"
    explanation: Epidemiology review lists facial coarsening among clinical features of MPS IV, supporting soft-tissue facial involvement within the MPS spectrum.
- name: Hepatosplenomegaly
  description: >
    Enlargement of liver and spleen from GAG storage in
    reticuloendothelial cells.
  phenotype_term:
    preferred_term: Hepatosplenomegaly
    term:
      id: HP:0001433
      label: Hepatosplenomegaly
  evidence:
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume"
    explanation: "Hepatosplenomegaly is a recognized MPS feature that responds to ERT, confirming organ enlargement from GAG storage."
- name: Cardiac Valve Disease
  description: >
    Progressive thickening and dysfunction of cardiac valves from
    GAG infiltration. Mitral and aortic valves most commonly affected.
  phenotype_term:
    preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
  evidence:
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "heart valve defects due to keratan sulphate accumulation"
    explanation: Morquio B patient series links GAG storage to heart valve defects, supporting the cardiac-valve node in the broader MPS spectrum.
- name: Corneal Clouding
  description: >
    Corneal opacification from GAG deposition in the corneal stroma.
    Characteristic of MPS I, IV, VI, and VII.
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: PMID:28595941
    reference_title: Epidemiology of mucopolysaccharidoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms include coarse facial features, umbilical hernia, pectus carinatum, joint contractures, corneal clouding, and hepatosplenomegaly."
    explanation: Epidemiology review lists corneal clouding among MPS VI symptoms, supporting corneal opacity within the MPS spectrum.
- name: Intellectual Disability
  description: >
    Neurocognitive decline from CNS GAG accumulation (heparan sulfate).
    Prominent in MPS I-H, II (severe), and III (Sanfilippo).
    Absent in MPS IV and VI.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    snippet: "ERT in the present formulations also does not cross the blood-brain barrier, with the consequence that the central nervous system is not cured by ERT"
    explanation: "CNS involvement causing intellectual disability is a major challenge as ERT cannot cross the blood-brain barrier."
  - reference: PMID:35216110
    reference_title: "Innate Immunity in Mucopolysaccharide Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in others, to cognitive decline, which is still a challenge for current therapies"
    explanation: "Cognitive decline is a characteristic feature that remains a therapeutic challenge in MPS."
  - reference: PMID:25624320
    reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
    supports: SUPPORT
    snippet: "Preservation of cognitive function at HCT and a younger age at transplantation were major predictors for superior cognitive development posttransplant"
    explanation: "Cognitive decline is a major concern in MPS I-H; early HCT can preserve cognitive function."
genetic:
- name: MPS I (IDUA Mutations)
  gene_term:
    preferred_term: IDUA
    term:
      id: hgnc:5391
      label: IDUA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Alpha-L-iduronidase deficiency. Spectrum from severe Hurler (MPS I-H)
    to attenuated Scheie (MPS I-S). Dermatan and heparan sulfate accumulation.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS I results from a mutation in the IDUA gene located on chromosome 4p16.3."
    explanation: Review identifies IDUA mutation as causal for MPS I.
  - reference: PMID:32780955
    reference_title: "Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "caused by deficiency of α-L-iduronidase, and consequent accumulation of dermatan and heparan sulfates"
    explanation: "Confirms alpha-L-iduronidase deficiency as the cause of MPS I with dermatan and heparan sulfate accumulation."
  - reference: PMID:32780955
    reference_title: "Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Severity of the disease ranges from mild (Scheie) to moderate (Hurler-Scheie) to severe (Hurler or MPS-IH)"
    explanation: "Confirms the clinical severity spectrum of MPS I from Scheie to Hurler."
- name: MPS II (IDS Mutations)
  gene_term:
    preferred_term: IDS
    term:
      id: hgnc:5389
      label: IDS
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Iduronate-2-sulfatase deficiency (Hunter syndrome). X-linked recessive.
    Dermatan and heparan sulfate accumulation. Severe and attenuated forms.
  evidence:
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is particularly important for severe forms of MPS I and MPS II characterized by cognitive decline"
    explanation: "Confirms MPS II has severe forms with cognitive decline."
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A mutation in the IDS gene, which locates on chromosome Xq28, leads to MPS II."
    explanation: Review supports IDS as the causal X-linked MPS II gene.
- name: MPS IIIA (SGSH Mutations)
  gene_term:
    preferred_term: SGSH
    term:
      id: hgnc:10818
      label: SGSH
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Sanfilippo syndrome type A. Heparan-N-sulfatase deficiency impairs heparan
    sulfate degradation and is part of the neuronopathic MPS III spectrum.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS IIIA arises from a mutation in the SGSH gene located on chromosome 17q25.3."
    explanation: Review identifies SGSH mutation as causal for MPS IIIA.
- name: MPS IIIB (NAGLU Mutations)
  gene_term:
    preferred_term: NAGLU
    term:
      id: hgnc:7632
      label: NAGLU
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Sanfilippo syndrome type B. Alpha-N-acetylglucosaminidase deficiency impairs
    heparan sulfate degradation and contributes to the neuronopathic MPS III
    spectrum.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A mutation in the NAGLU gene, located on chromosome 17q21, results in MPS IIIB disorder."
    explanation: Review identifies NAGLU mutation as causal for MPS IIIB.
- name: MPS IIIC (HGSNAT Mutations)
  gene_term:
    preferred_term: HGSNAT
    term:
      id: hgnc:26527
      label: HGSNAT
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Sanfilippo syndrome type C. HGSNAT deficiency impairs acetylation-dependent
    lysosomal heparan sulfate degradation and produces neuronopathic MPS III.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the HGSNAT gene, located on chromosome 8p11.1, cause MPS IIIC."
    explanation: Review identifies HGSNAT mutation as causal for MPS IIIC.
- name: MPS IIID (GNS Mutations)
  gene_term:
    preferred_term: GNS
    term:
      id: hgnc:4422
      label: GNS
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Sanfilippo syndrome type D. N-acetylglucosamine-6-sulfatase deficiency
    impairs heparan sulfate degradation and produces the rarest MPS III subtype.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS IIID is caused by a mutation in the GNS gene locating on chromosome 12q14."
    explanation: Review identifies GNS mutation as causal for MPS IIID.
- name: MPS IVA (GALNS Mutations)
  gene_term:
    preferred_term: GALNS
    term:
      id: hgnc:4122
      label: GALNS
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Morquio syndrome type A. N-acetylgalactosamine-6-sulfatase deficiency
    causes keratan sulfate and chondroitin-6-sulfate accumulation, severe
    skeletal dysplasia, joint laxity, and usually preserved cognition.
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS) due to a mutation in the GALNS gene"
    explanation: Morquio A guidelines identify GALNS mutations and enzyme deficiency as causal for MPS IVA.
- name: MPS IVB (GLB1 Mutations)
  gene_term:
    preferred_term: GLB1
    term:
      id: hgnc:4298
      label: GLB1
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Morquio syndrome type B. Beta-galactosidase deficiency within the GLB1
    spectrum causes keratan sulfate accumulation, dysostosis multiplex, ligament
    laxity, corneal clouding, and heart-valve disease with generally preserved
    neurologic development.
  evidence:
  - reference: PMID:21497194
    reference_title: "GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GM1 gangliosidosis and Morquio B are autosomal recessive storage disorders caused by the deficiency of β-galactosidase (GLB1)"
    explanation: Review supports GLB1 beta-galactosidase deficiency as causal for Morquio B / MPS IVB.
- name: MPS VI (ARSB Mutations)
  gene_term:
    preferred_term: ARSB
    term:
      id: hgnc:714
      label: ARSB
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Maroteaux-Lamy syndrome. Arylsulfatase B deficiency impairs chondroitin
    4-sulfate and dermatan sulfate degradation, producing somatic MPS features
    with usually preserved intelligence.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS VI is caused by a mutation in the ARSB (or 4S) gene located on chromosome 5q11–q13."
    explanation: Review identifies ARSB mutation as causal for MPS VI.
- name: MPS VII (GUSB Mutations)
  gene_term:
    preferred_term: GUSB
    term:
      id: hgnc:4696
      label: GUSB
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Sly syndrome. Beta-glucuronidase deficiency impairs chondroitin sulfate,
    dermatan sulfate, and heparan sulfate degradation and can include hydrops
    fetalis, skeletal disease, and neurodevelopmental involvement.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS VII is rooted in a mutation in the GUSB gene located on chromosome 7q21.11."
    explanation: Review identifies GUSB mutation as causal for MPS VII.
- name: MPS IX (HYAL1 Mutations)
  gene_term:
    preferred_term: HYAL1
    term:
      id: hgnc:5320
      label: HYAL1
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Hyaluronidase deficiency. HYAL1 pathogenic variants impair hyaluronan
    degradation and cause an extremely rare, milder MPS phenotype with short
    stature and soft-tissue masses.
  evidence:
  - reference: PMID:33578874
    reference_title: "Epidemiology of Mucopolysaccharidoses Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS IX arises from a mutation in the HYAL1 gene located on chromosome 3p21.3–p21.2."
    explanation: Review identifies HYAL1 mutation as causal for MPS IX.
treatments:
- name: Enzyme Replacement Therapy
  description: >
    Intravenous recombinant enzyme infusions for MPS I (laronidase),
    MPS II (idursulfase), MPS IVA (elosulfase alfa), MPS VI
    (galsulfase), and MPS VII (vestronidase alfa). Improves somatic
    features but does not cross the blood-brain barrier effectively.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_mechanisms:
  - target: Lysosomal GAG Accumulation
    treatment_effect: RESTORES
    description: Recombinant lysosomal enzymes reduce urinary GAGs and hepatosplenic storage burden in treatable MPS subtypes.
    evidence:
    - reference: PMID:30442189
      reference_title: "Enzyme replacement therapy: efficacy and limitations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "While ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume"
      explanation: Review supports ERT-mediated reduction of the storage biomarker and hepatosplenic burden.
  evidence:
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    snippet: "Enzyme replacement therapy (ERT) is available for mucopolysaccharidosis (MPS) I, MPS II, MPS VI, and MPS IVA"
    explanation: "Confirms ERT availability for MPS I, II, VI, and IVA."
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    snippet: "ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume, cartilaginous organs such as the trachea and bronchi, bones and eyes are poorly impacted by ERT probably due to limited penetration in the specific tissue"
    explanation: "ERT is effective for some features but has limited impact on cartilage, bones, and eyes."
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    snippet: "ERT in the present formulations also does not cross the blood-brain barrier, with the consequence that the central nervous system is not cured by ERT"
    explanation: "Major limitation of ERT is inability to cross the blood-brain barrier for CNS disease."
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    snippet: "All patients develop anti-ERT antibodies but only a few have drug-related adverse reactions"
    explanation: "Immunogenicity is universal but rarely clinically significant."
- name: Hematopoietic Stem Cell Transplantation
  description: >
    HSCT provides a permanent source of enzyme-producing donor cells.
    Most effective when performed before age 2 in MPS I-H (Hurler).
    Can stabilize neurocognitive outcomes by providing CNS enzyme
    via donor-derived microglia.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
  target_mechanisms:
  - target: Lysosomal GAG Accumulation
    treatment_effect: RESTORES
    description: Donor-derived hematopoietic cells can restore lysosomal enzyme activity, especially in severe MPS I.
    evidence:
    - reference: PMID:25624320
      reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A normal α-l-iduronidase enzyme level obtained post-HCT was another highly significant predictor for superior long-term outcome in most organ systems"
      explanation: HCT outcome study supports restored alpha-L-iduronidase activity as a determinant of improved organ outcomes.
  - target: CNS storage and neuroinflammation
    treatment_effect: MODULATES
    description: Early HCT can preserve neurocognitive outcomes when performed before substantial cognitive decline.
    evidence:
    - reference: PMID:25624320
      reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Preservation of cognitive function at HCT and a younger age at transplantation were major predictors for superior cognitive development posttransplant"
      explanation: HCT cohort links early transplantation and pre-existing cognitive status to superior cognitive outcomes.
  evidence:
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    snippet: "For severe MPS I patients (Hurler), early haematopoietic stem cell transplantation is the gold standard"
    explanation: "Confirms HSCT as gold standard for severe MPS I."
  - reference: PMID:25624320
    reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
    supports: SUPPORT
    snippet: "Two hundred seventeen patients with MPS-IH successfully engrafted with a median follow-up age of 9.2 years were included in this retrospective analysis"
    explanation: "Large multicenter study of 217 HCT patients demonstrates long-term outcomes."
  - reference: PMID:25624320
    reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
    supports: SUPPORT
    snippet: "Considerable residual disease burden was observed in the majority of the transplanted patients with MPS-IH, with high variability between patients"
    explanation: "Despite HCT, substantial residual disease burden persists, highlighting limitations of current treatment."
  - reference: PMID:25624320
    reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
    supports: SUPPORT
    snippet: "Preservation of cognitive function at HCT and a younger age at transplantation were major predictors for superior cognitive development posttransplant"
    explanation: "Early transplantation before cognitive decline is critical for optimal neurodevelopmental outcomes."
  - reference: PMID:25624320
    reference_title: "Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study."
    supports: SUPPORT
    snippet: "A normal α-l-iduronidase enzyme level obtained post-HCT was another highly significant predictor for superior long-term outcome in most organ systems"
    explanation: "Full donor chimerism with normal enzyme levels is essential for best long-term outcomes across organ systems."
- name: Supportive Orthopedic Care
  description: >
    Spinal surgery for cervical instability (especially MPS IV),
    joint replacement, carpal tunnel release, and management of
    kyphosis and scoliosis.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hip subluxation can be managed using pelvic and femoral osteotomy, shelf acetabuloplasty, or total hip arthroplasty"
    explanation: Guidelines support orthopedic surgical management for MPS skeletal complications.
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interventions for spinal cord compression in patients with Morquio A syndrome include spinal decompression, fusion or a combination of both"
    explanation: Guidelines support spinal decompression and fusion for cord-compression complications.
  - reference: PMID:32780955
    reference_title: "Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease."
    supports: SUPPORT
    snippet: "thoracolumbar kyphosis is an early manifestation in humans"
    explanation: "Early skeletal manifestations like thoracolumbar kyphosis require orthopedic monitoring and intervention."
datasets: []
references:
- reference: DOI:10.1016/j.isci.2024.108959
  title: Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis IIIB
  findings: []
- reference: DOI:10.3390/biomedicines11041067
  title: 'Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases'
  findings: []
- reference: DOI:10.3390/cimb46030169
  title: 'Cellular Organelle-Related Transcriptomic Profile Abnormalities in Neuronopathic Types of Mucopolysaccharidosis: A Comparison with Other Neurodegenerative Diseases'
  findings: []
- reference: DOI:10.3390/ijms25021113
  title: Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy
  findings: []
📚

References & Deep Research

References

4
DOI:10.1016/j.isci.2024.108959
Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis IIIB
No top-level findings curated for this source.
DOI:10.3390/biomedicines11041067
Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases
No top-level findings curated for this source.
DOI:10.3390/cimb46030169
Cellular Organelle-Related Transcriptomic Profile Abnormalities in Neuronopathic Types of Mucopolysaccharidosis: A Comparison with Other Neurodegenerative Diseases
No top-level findings curated for this source.
DOI:10.3390/ijms25021113
Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Mucopolysaccharidosis
  • Category: Mendelian
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 31

Key Pathophysiology Nodes

  • Lysosomal GAG Accumulation
  • Secondary Inflammatory Response
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.isci.2024.108959
  • DOI:10.3390/biomedicines11041067
  • DOI:10.3390/cimb46030169
  • DOI:10.3390/ijms25021113
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 13 citations 2026-02-10T18:25:31.023583

Disease Pathophysiology Research Report

Target Disease - Disease Name: Mucopolysaccharidosis (MPS) - MONDO ID: MONDO_0019249 (mucopolysaccharidosis) (derived from OpenTargets search metadata) - Category: Mendelian

1) Core Pathophysiology: Concepts, Definitions, and Current Understanding - Definition and unifying mechanism: MPS comprise inherited lysosomal storage disorders caused by deficiency of specific lysosomal hydrolases or sulfatases required for ordered degradation of glycosaminoglycans (GAGs). Primary substrates accumulate in lysosomes as proteoglycan-derived HS, DS, CS, KS, and HA, causing multi-organ dysfunction including CNS, skeletal, and cardiac disease (ago2024molecularmechanismsin pages 2-3, ago2024molecularmechanismsin pages 1-2). “MPSs are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down…glycosaminoglycans (GAGs). These GAGs accumulate over time…disrupt…autophagy, and mitochondrial function…increase oxidative stress and activate innate immunity and inflammation” (IJMS, Jan 2024; https://doi.org/10.3390/ijms25021113) (ago2024molecularmechanismsin pages 1-2). - Staged progression: Recent synthesis highlights a sequence from reversible early storage to irreversible organ injury: “(1) disruption of substrate degradation with pathogenic changes in lysosomal function, (2) cellular dysfunction, secondary/tertiary accumulation (GM2/GM3 ganglioside, etc.), and inflammatory process, and (3) progressive tissue/organ damage and cell death (e.g., skeletal dysplasia, CNS impairment)” (IJMS, Jan 2024) (ago2024molecularmechanismsin pages 1-2). The same review emphasizes limits of current ERT/HSCT and rationale for BBB-penetrant strategies (ago2024molecularmechanismsin pages 2-3). - Systems perspective of lysosomal dysfunction: Beyond storage, lysosomes regulate vesicle trafficking, signaling, and autophagy; their dysfunction propagates organelle stress, oxidative injury, and inflammation. MPS “perturbs intracellular trafficking and autophagy,” and GAGs can activate innate immunity with cytokine induction; mitochondrial dysfunction contributes to inflammation and ROS elevation (K. Mikołajczak 2025; overview) (mikołajczak2025lysosomalstoragediseases pages 1-4, mikołajczak2025lysosomalstoragediseases pages 10-13).

2) Molecular Pathways and Cellular Processes Affected - Primary substrate accumulation by GAG species and subtypes: Representative mapping—MPS I (IDUA deficiency; HS/DS), MPS II (IDS deficiency; HS/DS), MPS IIIA/IIIB (SGSH/NAGLU; HS), MPS IVA (GALNS; KS±CS), MPS VI (ARSB; DS) (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, ago2024molecularmechanismsin pages 2-3). - Secondary storage: Accumulation of gangliosides (GM2, GM3) is reported as secondary/tertiary storage during progression (IJMS, 2024) (ago2024molecularmechanismsin pages 1-2). - Autophagy-lysosome pathway alterations: In MPS IIIB models, “metabolic rewiring and autophagy inhibition correct lysosomal storage disease,” with AMPK inhibition reducing HS storage and NK1 (HGF spliced variant) engaging PI3K/Akt, decreasing autophagy/lysosome markers (BCN1, LC3, LAMP1) (iScience, Mar 2024; https://doi.org/10.1016/j.isci.2024.108959) (scarcella2024metabolicrewiringand pages 10-12). These experiments provide mechanistic links among energy sensing (AMPK), PI3K/Akt signaling, and autophagy flux in the context of lysosomal HS storage (scarcella2024metabolicrewiringand pages 10-12). - Mitochondrial dysfunction and metabolic shifts: Brain metabolomics in MPS IIIB indicate broad rewiring (e.g., altered lactate and glutamine), consistent with mitochondrial/energy pathway disruption (iScience, 2024) (scarcella2024metabolicrewiringand pages 10-12). Reviews emphasize mitochondrial dysfunction accompanying GAG accumulation (IJMS, 2024) (ago2024molecularmechanismsin pages 1-2) and oxidative stress in MPS (overview) (mikołajczak2025lysosomalstoragediseases pages 1-4). - ER and Golgi stress; trafficking defects: Transcriptomics in neuronopathic MPS fibroblasts showed dysregulation of organelle-associated genes and EM evidence of structural disruptions—particularly Golgi apparatus fragmentation and ER stress markers. Up-regulated PDIA3 and MFGE8, down-regulated ARL6IP6, ABHD5, PDE4DIP, YIPF5, CLDN11; increased GM130 (GOLGA2) expression; mechanistic links to impaired ER-to-Golgi transport and Golgi fragmentation (CIMB, Mar 2024; https://doi.org/10.3390/cimb46030169) (wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10). The study notes that Golgi fragmentation “can precede neuronal cell death,” and perturbations in GRASP55/65 alter HS/CS synthesis and secretion, directly linking Golgi structure to GAG handling (wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18). - Neuroinflammation and innate immune signaling: Reviews and cross-LSD analyses implicate microglial/astrocyte activation with upregulated cytokines/chemokines, and highlight TLR pathways and inflammasome activation in LSDs, also relevant to MPS; authors synthesize “pro-inflammatory immunological mediators” in LSD neuroinflammation (Biomedicines, Apr 2023; https://doi.org/10.3390/biomedicines11041067) (wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10). Contemporary MPS-focused reviews underscore a “profound relationship between immunity and MPS,” with complex inflammatory pathways (IJMS, 2024) (ago2024molecularmechanismsin pages 2-3). - Synaptic and circuit dysfunction: Neuronopathic MPS subtypes (e.g., MPS III) show pronounced CNS involvement with organelle stress signatures that plausibly impact synaptic homeostasis; organelle gene changes (e.g., GOLGA2, PDIA3) and mitochondrial stress are consistent with synaptic/autophagic deficits that drive neurodegeneration, though direct synaptic electrophysiology data were not retrieved in this evidence batch (CIMB, 2024; IJMS, 2024) (wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10, ago2024molecularmechanismsin pages 1-2). - Skeletal dysplasia mechanisms: Threshold storage in bone (notably growth plate) engages chondrocytes/osteoblasts/osteoclasts and becomes refractory to reversal once exceeded (IJMS, 2024) (ago2024molecularmechanismsin pages 2-3). Connective-tissue GAG storage (e.g., KS in MPS IVA; DS in MPS VI) disrupts ECM organization, secretion/trafficking, and growth plate architecture (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10). - Cardiac valve/myocardial disease: Reviews capture multi-system involvement with heart valves and myocardium impacted by GAG deposition and secondary inflammatory/oxidative mechanisms (IJMS, 2024; overview 2025) (ago2024molecularmechanismsin pages 2-3, mikołajczak2025lysosomalstoragediseases pages 10-13).

3) Key Molecular Players - Genes/Proteins (HGNC): IDUA (MPS I), IDS (MPS II), SGSH (MPS IIIA), NAGLU (MPS IIIB), GALNS (MPS IVA), ARSB (MPS VI). Additional organelle/stress markers: GOLGA2 (GM130), PDIA3, MFGE8, ARL6IP6, ABHD5, PDE4DIP, YIPF5, CLDN11; lysosome/autophagy markers LAMP1, LC3, BECN1; signaling axes AMPK, PI3K/Akt (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10, scarcella2024metabolicrewiringand pages 10-12). - Chemical entities (metabolites/small molecules; CHEBI): Heparan sulfate (HS), dermatan sulfate (DS), chondroitin sulfate (CS), keratan sulfate (KS), hyaluronan (HA); gangliosides GM2/GM3 (secondary storage); pathway modulators used experimentally (AICAr, SBI-0206965) and NK1 protein therapy concept (iScience 2024) (ago2024molecularmechanismsin pages 1-2, scarcella2024metabolicrewiringand pages 10-12). - Cell types (CL): Neurons, microglia (CL:0000129), astrocytes (CL:0000127), chondrocytes, osteoblasts, osteoclasts, fibroblasts (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2). - Anatomical locations (UBERON): Brain (UBERON:0000955), spinal cord, heart/valves (UBERON:0001911), growth plate cartilage (UBERON:0002418), bone, connective tissues (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3).

4) Biological Processes (GO terms) Disrupted - Lysosomal organization/function and autophagy: GO:0005773 (vacuole/lysosome), GO:0006914 (autophagy), GO:0016236 (macroautophagy), GO:0006629 (lipid metabolism) (ago2024molecularmechanismsin pages 1-2, scarcella2024metabolicrewiringand pages 10-12). - Innate immune/inflammatory signaling: GO:0006954 (inflammatory response), GO:0002224 (TLR signaling) and inflammasome-related pathways (supported at review level for LSDs with MPS relevance) (wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10, ago2024molecularmechanismsin pages 2-3). - Organelle stress and trafficking: GO:0006457 (protein folding), GO:0006888 (ER to Golgi vesicle-mediated transport), GO:0007030 (Golgi organization), GO:0007005 (mitochondrion organization) (wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10). - ECM organization and skeletal development: GO:0030198 (extracellular matrix organization), GO:0001501 (skeletal system development) (ago2024molecularmechanismsin pages 2-3, ago2024molecularmechanismsin pages 1-2).

5) Cellular Components - Key loci of pathology: Lysosomes (GO:0005764/0005773), autophagosomes (GO:0005776), ER (GO:0005783), Golgi (GO:0005794), mitochondria (GO:0005739), synapses (GO:0045202) (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18, scarcella2024metabolicrewiringand pages 10-12).

6) Disease Progression: Sequence of Events - Early/reversible storage: Initial HS/DS/KS/CS/HA accumulation within lysosomes (often as proteoglycans) with cellular stress responses that may be reversible if treated early (IJMS, 2024) (ago2024molecularmechanismsin pages 1-2). - Escalation: Lysosomal dysfunction leads to autophagy impairment, ER/Golgi stress, impaired trafficking and secretion, mitochondrial dysfunction with oxidative stress, and activation of innate immunity (microglia/astrocytes). Secondary/tertiary storage of gangliosides (GM2/GM3) emerges (IJMS, 2024; overview 2025) (ago2024molecularmechanismsin pages 1-2, mikołajczak2025lysosomalstoragediseases pages 1-4). - Organ damage: Progressive neuronal synaptic/circuit dysfunction and neurodegeneration; growth plate and bone dysplasia becoming refractory beyond storage thresholds; heart valve/myocardial pathology; multi-organ failure (IJMS, 2024) (ago2024molecularmechanismsin pages 2-3, ago2024molecularmechanismsin pages 1-2).

7) Phenotypic Manifestations and Mechanistic Links (HPO terms suggested) - Neurocognitive regression, behavioral disturbances, seizures (HPO:0001263, HPO:0000708): Associated with HS-driven neuroinflammation, autophagy/mitochondrial dysfunction, and organelle stress in neuronopathic MPS (IJMS 2024; CIMB 2024) (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2). - Skeletal dysplasia (HPO:0002652), short stature (HPO:0004322), joint contractures (HPO:0001371): Linked to GAG storage in cartilage/bone, secretory and ECM disorganization, chondrocyte dysfunction, and inflammation (IJMS 2024) (ago2024molecularmechanismsin pages 2-3, ago2024molecularmechanismsin pages 1-2). - Cardiac valvular disease (HPO:0001657), cardiomyopathy (HPO:0001638): Driven by storage/inflammation/oxidative stress in valves and myocardium (IJMS 2024; overview) (ago2024molecularmechanismsin pages 2-3, mikołajczak2025lysosomalstoragediseases pages 10-13).

8) Current Applications and Real-World Implementations (mechanistic perspective) - Enzyme replacement therapy (ERT) and HSCT: Cross-correction concept underlies current care. However, IV ERT has limited CNS efficacy due to BBB; HSCT carries donor/GvHD risks and is timing-sensitive. New strategies (intrathecal/intracerebroventricular ERT; receptor-mediated “molecular Trojan horse” enzymes) are proposed to target CNS and bone (IJMS, Jan 2024; https://doi.org/10.3390/ijms25021113) (ago2024molecularmechanismsin pages 2-3). “Several potential treatments…that can penetrate the blood–brain barrier and bone have been proposed…including targeting peptides and molecular Trojan horses…Gene therapy trials with AAV, ex vivo LV…are proposed and/or underway” (IJMS, 2024) (ago2024molecularmechanismsin pages 1-2). - Experimental pathway modulation: In MPS IIIB cells/brain, AMPK inhibition and PI3K/Akt activation (via NK1) reduce HS storage and normalize autophagy-lysosome markers, supporting metabolism–autophagy–lysosome crosstalk as a therapeutic lever (iScience, Mar 2024) (scarcella2024metabolicrewiringand pages 10-12).

9) Relevant Statistics and Data (recent) - Incidence: Approximate overall MPS incidence cited as ~1 in 20,000 live births (review synthesis) (ago2024molecularmechanismsin pages 1-2). - Quantitative molecular readouts in MPS IIIB models: AMPK inhibition reduced HS storage and lysosomal vacuolization after 24 h; brain metabolomics revealed significant changes in lactate and glutamine, among others (p/q values significant; detailed figures in iScience 2024) (scarcella2024metabolicrewiringand pages 10-12).

10) Embedded Artifact: Subtype-to-mechanism summary table | Subtype | Causal gene (HGNC) | Enzyme name | Primary stored GAG(s) | Key affected cells (CL terms) | Key organs/tissues (UBERON terms) | Key disrupted processes (GO terms) | Selected molecular notes | Evidence (citation IDs) | |---|---|---|---|---|---|---|---|---| | MPS I | IDUA | alpha-L-iduronidase | Heparan sulfate (HS); Dermatan sulfate (DS) | Microglia (CL:0000129), Astrocytes (CL:0000127), Chondrocytes | Brain (UBERON:0000955); Heart (UBERON:0001911); Growth plate cartilage (UBERON:0002418) | Lysosomal vacuole (GO:0005773); Autophagy (GO:0006914); Inflammatory response (GO:0006954) | Primary HS/DS accumulation → lysosomal dysfunction, secondary substrate perturbation, neuroinflammation and skeletal damage | (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, mikołajczak2025lysosomalstoragediseases pages 1-4) | | MPS II | IDS | iduronate 2-sulfatase | Heparan sulfate (HS); Dermatan sulfate (DS) | Microglia (CL:0000129), Astrocytes (CL:0000127), Osteoblasts/Chondrocytes | Brain (UBERON:0000955); Heart (UBERON:0001911); Growth plate cartilage (UBERON:0002418) | Lysosomal dysfunction (GO:0005773); Autophagy (GO:0006914); Inflammatory response (GO:0006954) | CNS involvement varies with residual IDS activity; systemic GAG deposition drives skeletal and cardiac pathology | (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, mikołajczak2025lysosomalstoragediseases pages 1-4) | | MPS IIIA | SGSH | N-sulfoglucosamine sulfohydrolase | Heparan sulfate (HS) (predominantly neuronal storage) | Microglia (CL:0000129), Astrocytes (CL:0000127), Neurons | Brain (UBERON:0000955); Spinal cord | Lysosome/vacuole (GO:0005773); Autophagy (GO:0006914); Inflammatory response (GO:0006954) | Neuronopathic phenotype: HS-driven microglial activation, organelle (ER/Golgi) stress and altered organelle gene expression linked to neurodegeneration | (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10) | | MPS IIIB | NAGLU | alpha-N-acetylglucosaminidase | Heparan sulfate (HS) | Microglia (CL:0000129), Astrocytes (CL:0000127), Neurons | Brain (UBERON:0000955); Peripheral tissues | Lysosome (GO:0005773); Autophagy (GO:0006914); Inflammatory response (GO:0006954) | Autophagy–lysosome dysregulation and metabolic rewiring (AMPK/PI3K-Akt changes) correct storage in models; metabolic/mitochondrial perturbation accompanies HS storage | (scarcella2024metabolicrewiringand pages 10-12, ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2) | | MPS IVA | GALNS | galactosamine (N-acetyl)-6-sulfatase | Keratan sulfate (KS) ± chondroitin sulfate (CS) | Chondrocytes, Osteoblasts, Fibroblasts; (microglia/astrocytes in rare CNS cases) | Growth plate cartilage (UBERON:0002418); Bone; Heart (UBERON:0001911) | Lysosomal dysfunction (GO:0005773); ECM organization; Autophagy (GO:0006914) | Predominant skeletal/connective-tissue disease (KS accumulation); Golgi/ER trafficking and secretion disturbances affect GAG handling and matrix assembly | (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10) | | MPS VI | ARSB | arylsulfatase B | Dermatan sulfate (DS) | Chondrocytes, Osteoclasts/Osteoblasts, Fibroblasts | Growth plate cartilage (UBERON:0002418); Heart (valves) (UBERON:0001911); Skin | Lysosomal dysfunction (GO:0005773); Autophagy (GO:0006914); Inflammatory response (GO:0006954) | Severe somatic/skeletal disease from DS storage; inflammation and oxidative stress contribute to progressive tissue damage | (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, mikołajczak2025lysosomalstoragediseases pages 1-4) |

Table: Compact mapping of key MPS subtypes showing causal genes, enzymes, principal stored GAGs, affected cells/tissues, disrupted GO processes, brief molecular notes, and source citations; useful as an ontology-ready summary for disease knowledgebases. Evidence is drawn from the provided context (mikołajczak2025lysosomalstoragediseases pages 1-4, mikołajczak2025lysosomalstoragediseases pages 10-13).

Gene/Protein Annotations and Ontology Mapping - HGNC: IDUA, IDS, SGSH, NAGLU, GALNS, ARSB; organelle/stress markers: GOLGA2, PDIA3, MFGE8, ARL6IP6, ABHD5, PDE4DIP, YIPF5, CLDN11 (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10, scarcella2024metabolicrewiringand pages 10-12). - GO Biological Processes: autophagy (GO:0006914), inflammatory response (GO:0006954), ER to Golgi transport (GO:0006888), Golgi organization (GO:0007030), mitochondrial organization (GO:0007005), ECM organization (GO:0030198) (scarcella2024metabolicrewiringand pages 10-12, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18, ago2024molecularmechanismsin pages 2-3). - Cellular Components: lysosome/vacuole (GO:0005773), ER (GO:0005783), Golgi (GO:0005794), mitochondrion (GO:0005739), synapse (GO:0045202) (ago2024molecularmechanismsin pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18). - Cell Types (CL): microglia (CL:0000129), astrocyte (CL:0000127), neuron, chondrocyte, osteoblast, osteoclast, fibroblast (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3, wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2). - Anatomical (UBERON): brain (UBERON:0000955), heart (UBERON:0001911), growth plate cartilage (UBERON:0002418), bone (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3). - Chemical Entities (CHEBI): heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate, hyaluronan; GM2/GM3 gangliosides; AICAr; SBI-0206965 (ago2024molecularmechanismsin pages 1-2, scarcella2024metabolicrewiringand pages 10-12).

Expert Opinions and Analysis - Contemporary reviews converge on an expanded view of lysosomal biology, where primary GAG storage triggers multi-organelle stress responses and maladaptive signaling, notably in autophagy-lysosome and innate immune axes. The staged progression model rationalizes why early intervention is crucial for CNS and skeletal outcomes and why bone disease is especially refractory after a threshold of growth-plate storage is exceeded (ago2024molecularmechanismsin pages 2-3, ago2024molecularmechanismsin pages 1-2). Emerging experimental data (MPS IIIB) corroborate that tuning energy sensors (AMPK) and autophagy-related signaling (PI3K/Akt) can reduce storage and normalize lysosomal/autophagic markers, suggesting tractable nodes for adjunctive therapy alongside substrate- or gene-directed approaches (scarcella2024metabolicrewiringand pages 10-12). Organelle transcriptomics and ultrastructural data tie neuronopathic phenotypes to ER/Golgi/mitochondrial derangements that likely impinge on synaptic function and neuronal viability (wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18).

Citations with URLs and Dates - Ago Y, Rintz E, Musini KS, Ma Z, Tomatsu S. Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy. International Journal of Molecular Sciences. 2024 Jan;25(2):1113. URL: https://doi.org/10.3390/ijms25021113 (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 2-3). - Scarcella M, et al. Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis IIIB. iScience. 2024 Mar;27(3):108959. URL: https://doi.org/10.1016/j.isci.2024.108959 (scarcella2024metabolicrewiringand pages 10-12). - Wiśniewska K, et al. Cellular Organelle-Related Transcriptomic Profile Abnormalities in Neuronopathic Types of MPS. Current Issues in Molecular Biology. 2024 Mar;46:2678–2700. URL: https://doi.org/10.3390/cimb46030169 (wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2, wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18, wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10). - Pandey MK. Exploring Pro-Inflammatory Immunological Mediators: Neuroinflammation in LSDs. Biomedicines. 2023 Apr;11(4):1067. URL: https://doi.org/10.3390/biomedicines11041067 (wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10). - Mikołajczak K. Lysosomal storage diseases as a complex pathophysiological and clinical problem—part one. 2025 (overview). Mechanistic statements on inflammation/oxidative stress and multi-organ involvement used as supportive background (mikołajczak2025lysosomalstoragediseases pages 1-4, mikołajczak2025lysosomalstoragediseases pages 10-13).

Limitations - Some mechanistic details (e.g., definitive roles for TLR4, inflammasome, cGAS-STING specifically in MPS brain) are supported here at the review level across LSDs and MPS-focused reviews without new 2024 primary data in this evidence batch. Direct synaptic physiology evidence and detailed cardiac histopathology from 2023–2024 primary studies were not captured in the retrieved set; claims were framed accordingly (wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10, ago2024molecularmechanismsin pages 2-3).

References

  1. (ago2024molecularmechanismsin pages 1-2): Yasuhiko Ago, Estera Rintz, Krishna Sai Musini, Zhengyu Ma, and Shunji Tomatsu. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. International Journal of Molecular Sciences, 25:1113, Jan 2024. URL: https://doi.org/10.3390/ijms25021113, doi:10.3390/ijms25021113. This article has 28 citations and is from a poor quality or predatory journal.

  2. (ago2024molecularmechanismsin pages 2-3): Yasuhiko Ago, Estera Rintz, Krishna Sai Musini, Zhengyu Ma, and Shunji Tomatsu. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. International Journal of Molecular Sciences, 25:1113, Jan 2024. URL: https://doi.org/10.3390/ijms25021113, doi:10.3390/ijms25021113. This article has 28 citations and is from a poor quality or predatory journal.

  3. (mikołajczak2025lysosomalstoragediseases pages 1-4): K Mikołajczak. Lysosomal storage diseases as a complex pathophysiological and clinical problem-part one. Unknown journal, 2025.

  4. (scarcella2024metabolicrewiringand pages 10-12): Melania Scarcella, Gianluca Scerra, Mariangela Ciampa, Marianna Caterino, Michele Costanzo, Laura Rinaldi, Antonio Feliciello, Serenella Anzilotti, Chiara Fiorentino, Maurizio Renna, Margherita Ruoppolo, Luigi Michele Pavone, Massimo D’Agostino, and Valeria De Pasquale. Metabolic rewiring and autophagy inhibition correct lysosomal storage disease in mucopolysaccharidosis iiib. iScience, 27:108959, Mar 2024. URL: https://doi.org/10.1016/j.isci.2024.108959, doi:10.1016/j.isci.2024.108959. This article has 7 citations and is from a peer-reviewed journal.

  5. (wisniewska2024cellularorganellerelatedtranscriptomic pages 1-2): Karolina Wiśniewska, Lidia Gaffke, Magdalena Żabińska, Grzegorz Węgrzyn, and Karolina Pierzynowska. Cellular organelle-related transcriptomic profile abnormalities in neuronopathic types of mucopolysaccharidosis: a comparison with other neurodegenerative diseases. Current Issues in Molecular Biology, 46:2678-2700, Mar 2024. URL: https://doi.org/10.3390/cimb46030169, doi:10.3390/cimb46030169. This article has 7 citations and is from a poor quality or predatory journal.

  6. (wisniewska2024cellularorganellerelatedtranscriptomic pages 7-10): Karolina Wiśniewska, Lidia Gaffke, Magdalena Żabińska, Grzegorz Węgrzyn, and Karolina Pierzynowska. Cellular organelle-related transcriptomic profile abnormalities in neuronopathic types of mucopolysaccharidosis: a comparison with other neurodegenerative diseases. Current Issues in Molecular Biology, 46:2678-2700, Mar 2024. URL: https://doi.org/10.3390/cimb46030169, doi:10.3390/cimb46030169. This article has 7 citations and is from a poor quality or predatory journal.

  7. (mikołajczak2025lysosomalstoragediseases pages 10-13): K Mikołajczak. Lysosomal storage diseases as a complex pathophysiological and clinical problem-part one. Unknown journal, 2025.

  8. (wisniewska2024cellularorganellerelatedtranscriptomic pages 16-18): Karolina Wiśniewska, Lidia Gaffke, Magdalena Żabińska, Grzegorz Węgrzyn, and Karolina Pierzynowska. Cellular organelle-related transcriptomic profile abnormalities in neuronopathic types of mucopolysaccharidosis: a comparison with other neurodegenerative diseases. Current Issues in Molecular Biology, 46:2678-2700, Mar 2024. URL: https://doi.org/10.3390/cimb46030169, doi:10.3390/cimb46030169. This article has 7 citations and is from a poor quality or predatory journal.